BioCentury | Jun 3, 2013
Company News

Olon S.p.A., Salix deal

...Salix acquired worldwide rights to Olon's IP relating to amorphous rifaximin. The IP includes a pending...
...to amorphous rifaximin. The IP includes a pending patent application and an issued patent that Olon...
...and respiratory indications, including Crohn's disease (see BioCentury, July 8, 1996 & Aug, 13, 2012). Olon S.p.A....
Items per page:
1 - 1 of 1
BioCentury | Jun 3, 2013
Company News

Olon S.p.A., Salix deal

...Salix acquired worldwide rights to Olon's IP relating to amorphous rifaximin. The IP includes a pending...
...to amorphous rifaximin. The IP includes a pending patent application and an issued patent that Olon...
...and respiratory indications, including Crohn's disease (see BioCentury, July 8, 1996 & Aug, 13, 2012). Olon S.p.A....
Items per page:
1 - 1 of 1